Form Approved OMB No. 0920-1385 Exp. Date: 3/31/26

case report form: Eumycetoma
Patient demographic characteristics
Unique patient ID: (site_###)
Site submitting case:
Location of residence for patient (ZIP Code): OR [] Unknown
Age at diagnosis (years):
Sex: [] Male [] Female
Race and/or ethnicity (select all that apply and enter additional details in the spaces provided):
[] American Indian or Alaska Native
Enter, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Barrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, Maya, etc.
[] Asian – provide details below
[] Chinese [] Asian Indian [] Filipino [] Vietnamese [] Korean [] Japanese
Enter, for example, Pakistani, Hmong, Afghan, etc.
[] Black or African American – provide details below
[] African American [] Jamaican [] Haitian [] Nigerian [] Ethiopian [] Somali
Enter, for example, Trinidadian and Tobagonian, Ghanaian, Congolese, etc.
[] Hispanic or Latino – provide details below
[] Mexican [] Puerto Rican [] Salvadoran [] Cuban [] Dominican [] Guatemalan
Enter, for example, Colombian, Honduran, Spaniard, etc.
<del></del>

CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).

[] Middle Eastern or North African - provide details below

[] Lebanese   [] Iranian   [] Egyptian   [] Syrian   [] Iraqi   [] Israeli
Enter, for example, Moroccan, Yemeni, Kurdish, etc.
[] Native Hawaiian or Pacific Islander – provide details below
[] Native Hawaiian [] Samoan [] Chamorro [] Tongan [] Fijian [] Marshallese
Enter, for example, Chuukese, Palauan, Tahitian, etc.
[] White – provide details below
[] English [] German [] Irish [] Italian [] Polish [] Scottish
Enter, for example, French, Swedish, Norwegian, etc.
Monthly household income (USD)
Occupation at time of presumed infection:
ndustry at time of presumed infection:
Underlying medical conditions (active or present in the 2 years before symptom onset)
Diabetes mellitus [] Yes [] No [] Unknown
Chronic kidney disease [] Yes [] No [] Unknown If yes, on dialysis? [] Yes [] No [] Unknown
If yes, GFR < 60? [] Yes [] No
Liver cirrhosis? [] Yes [] No [] Unknown
Chronic hepatitis without cirrhosis? [] Yes [] No [] Unknown If yes, [] Hep B [] Hep C
mmunocompromising condition [] Yes [] No [] Unknown [] HIV infection
[] HIV infection without AIDS (CD4 ≥ 200)
[] HIV infection with AIDS (CD4 < 200) or chart diagnosis of advanced HIV disease [] Cancer diagnosis, specify
[] On chemotherapy, specify
Date of cancer diagnosis (mm/dd/yyyy): [] Transplant
[] Solid organ, specify organ
[] Hematologic (stem cell)

Date of transplantation (mm/dd/yyyy):
[] Immunosuppressive therapy, specify
[] Other immunocompromised condition, specify
Other major underlying condition not listed (specify):
Exposure history
Has patient traveled or lived internationally in their life? [] Yes [] No [] Unknown
O Country 1; Approximate duration of stay (years):
O Country 2; Approximate duration of stay (years):
O Country 3; Approximate duration of stay (years):
O Country 4; Approximate duration of stay (years):
O Country 5; Approximate duration of stay (years):
Did the patient immigrate to the United States? [] Yes [] No [] Unknown
If yes, date of immigration (mm/dd/yyyy):
If yes, country immigrated from:
Any traumatic inoculation ever recalled? [] Yes [] No [] Unknown
If yes, please describe geographic location (e.g., city, state):
If yes, please describe the material involved (e.g., thorns, branches):
If yes, please describe any weather events (e.g., hurricane, flood):
If yes, please indicate approximate date of traumatic inoculation (mm/dd/yyyy):
Most likely source of infection, according to clinician
Diagnosis
Did patient have health care facility visits (health center, hospital, etc.) for mycetoma symptoms before visit with mycetoma diagnosis? [] Yes [] No [] Unknown
If yes, how many visits?
Were there misdiagnoses before being diagnosed with mycetoma [] Yes [] No [] Unknown
What misdiagnoses, if any, did this patient have before being diagnosed with mycetoma (in the last 12 months):
Please list all misdiagnoses:
Laboratory testing (associated with diagnosis):
[] X-ray [] Not performed [] Unknown if performed
date of imaging:; result:
[] MRI [] Not performed [] Unknown if performed date of imaging:; result:
[] Ultrasound imaging [] Not performed [] Unknown if performed
date of imaging (mm/dd/yyyy):; result:

[] CT Scan [] Not performed [] Unknown if performed of imaging (mm/dd/yyyy):	; result: n if performed pe of stain: formed	
date (mm/dd/yyyy):; re [] Fungal grain culture [] Not performed [] Unki date of collection (mm/dd/yyyy): Organism(s):	nown if performed ; Positive/N	
[] Broad range sequencing [] Not performed []	Unknown if perform	ed
date of collection (mm/dd/yyyy):	; Type (e.g.	, 18s, ITS):
Positive/Negative: Org	ganism(s):	;
Signs and symptoms noted during patient into	erview:	
Signs & Symptoms	Yes/No	Onset Date if Known
Localized swelling		
Openings on the skin (sinuses)		
Discharge containing grains  Macroscopic grain size		
Microscopic grain size		
Lymph node involvement		
Bone involvement		
Pain		
Itching		
Other symptoms, please describe:		
Please describe the specific location on the boof for multiple areas affected):	dy of the mycetoma	esion(s) (please mark all that apply
[] Head and neck		
[] Trunk		
[] Upper limbs		
[] Buttocks, perineum, genitals		
[] Lower limbs		
Additional comments on anatomical location:		
Clinical size of mycetoma lesion: Length (cm): _	; Wi	dth (cm):
Color of grains:		
[] Black		
[] White/yellow		
[] Red		

[] No visible grains
Did mycetoma cause any form of disability: [] Yes [] No [] Unknown

If yes, please fill out the table below:

Disability	Yes/No	Onset Date	Number of days with disability	Inability to work (Y/N)
Mild motor impairment (has some difficulty in moving around but is able to walk without help)				
Moderate motor impairment (has some difficulty in moving around, and difficulty in lifting and holding objects, dressing and sitting upright, but is able to walk without help)				
Severe motor impairment (is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright)				

## **Treatment**

Was the patient trea	ated for eumyc	etoma?
[] Yes	[] No	[] Unknown

**If yes**, list all therapeutic agents (e.g., antifungals, immune response modulators, antibiotics, steroids) in the table below:

Therapeutic Agent Name	Max Daily dose (mg/day)	Route (e.g., IV, PO, IT)	Start Date	Duration of Therapy	Therapy Discontinued due to toxicity. at time of abstraction discontinued to toxicity.		Therapeutic Drug Monitoring (e.g., serum level of antifungal)
			//	days	[] Yes [] No	[] Yes [] No 	[] Yes [] No Level 1: Date: Value: Level 2: Date: Value
			//	days	[] Yes [] No	[] Yes [] No	[] Yes [] No Level 1: Date: Value: Level 2: Date: Value

			, ,		[] \( \( \)	n.	[] Yes [] No	[] Yes [] No
			//	days	[] Yes	[] No		- Lovel 1.
								Level 1:
								Date:
								Value:
								Laval O
								Level 2:
								Date:
							[] Vaa     [] Na	Value
			, ,	davia	[] \/aa	[] Na	[] Yes [] No	[] Yes [] No
			<u> </u>	days	[] Yes	[] No		Toyol 1.
								Level 1:
								Date:
								Value:
								Level 2:
								Date:
								Value
							[] Yes [] No	[] Yes [] No
			//	days	[] Yes	[] No	[] 103 [] 110	_ [] 103 [] 110
			''	uays	[] 103	[] [10		Level 1:
								Date:
								Value:
								Value.
								Level 2:
								Date:
								Value
							[] Yes [] No	[] Yes [] No
			/ /	days	[] Yes	[] No		
				,				- Level 1:
								Date:
								Value:
								Level 2:
								Date:
								Value
Notes about treat	ment:							
	_							
Did the patient un						[] Yes []	No [] Unknown	
If yes, dat	e of surgical	excision (	mm/dd/yyyy):					
Did the patient re	ceive antimi	crobials b	efore local sur	gical excision?	? [] Yes [	] No [] U	Jnknown	
Did the patient un					wn			
Complications:				=======				

Outcome	Yes/No	Onset Date	Notes (e.g., location)
Tissue fibrosis			
Ankylosis (abnormal stiffening			
and immobility of a joint due to			
fusion of the bones)			
Massive destruction of a joint			
Pulmonary eumycetoma due to			
secondary spread from a			
subcutaneous lesion			
Bronchopleural cutaneous fistula			
Secondary bacterial infection			
Amputation			
Lymphedema			
Other; specify			

Did	the my	vcetoma	infection	resolve	(clinical	and	radiogra	phic o	cure)? [	l Yes l	[] No [	[] Unknowr

If yes, what was the date of clinical resolution:

If no, what was date of last follow-up (mm/dd/yyyy):

Did this patient die within 2 years after the mycetoma diagnosis? [] Yes [] No [] Unknown

If yes, was mycetoma a contributing factor in patient's death? [] Yes [] No [] Unknown

Additional comments:		

## Appendix 2: Dermatology Life Quality Index Tool

Dermatology Life Quality Index Questionnaire:

- 1. Over the last week, how itchy, sore, painful, or stinging has your skin problem been?
  - a. Very much
  - b. A lot
  - c. A little
  - d. Not at all
- 2. Over the last week, how embarrassed or self-conscious have you been because of your skin problem?
  - a. Very much
  - b. A lot
  - c. A little
  - d. Not at all
- 3. Over the last week, how much has your skin problem interfered with you going shopping or looking after your home or garden?
  - a. Very much
  - b. A lot
  - c. A little
  - d. Not at all

- e. Not relevant
  4. Over the last week, how much has your skin problem influenced the clothes you wear?
  a. Very much
  b. A lot
  c. A little
  d. Not at all
  e. Not relevant
  5. Over the last week, how much has your skin problem affected any social or leisure activities?
  a. Very much
  - b. A lot
  - c. A little
  - d. Not at all
  - e. Not relevant
  - 6. Over the last week, how much has your skin problem made it difficult for your to do any sport?
    - a. Very much
    - b. A lot
    - c. A little
    - d. Not at all
    - e. Not relevant
  - 7. Over the last week, has your skin problem prevented you from working or studying
    - a. Yes
    - b. No
    - c. Not relevant
      - i. If no, over the last week how much has your skin problem been a problem at work or studying?
        - 1. A lot
        - 2. A little
        - 3. Not at all
  - 8. Over the last week, how much has your skin problem created problems with your partner or any of your close friends or relatives?
    - a. Very much
    - b. A lot
    - c. A little
    - d. Not at all
    - e. Not relevant
  - 9. Over the last week, how much has your skin problem caused any sexual difficulties?
    - a. Very much
    - b. A lot
    - c. A little
    - d. Not at all
    - e. Not relevant
  - 10. Over the last week, how much of a problem has the treatment for your skin problem been, for example by making your home messy, or by taking up time?
    - a. Very much
    - b. A lot
    - c. A little
    - d. Not at all
    - e. Not relevant